Ross James, Morcos Maya, Rowe Neal E
Department of Surgery, Division of Urology, University of Ottawa, Ottawa, ON, Canada.
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
World J Urol. 2025 Mar 26;43(1):189. doi: 10.1007/s00345-025-05576-7.
Ureterolysis is an uncommonly performed surgery for management of retroperitoneal fibrosis. This study sought to utilize a large, multi-centered database to assess the short-term post-operative outcomes of patients undergoing ureterolysis surgery for retroperitoneal fibrosis.
Using the American College of Surgeons National Quality Improvement Program database, a retrospective review was conducted on patients who underwent ureterolysis for retroperitoneal fibrosis between January 1st, 2006, and December 31st, 2016. Patients who underwent ureterolysis for retroperitoneal fibrosis as a principle operative procedure by a urologist were included. Complications within 30 days of surgery were captured and organized based on the Clavien-Dindo classification system. The prevalence of secondary reconstructive urologic procedures performed at the time of ureterolysis (ureteroureterostomy, ureteroneocystostomy, and ureteroneocystostomy with psoas hitch/bladder flap) was determined.
One hundred patients (51 male, 49 female) were included in the cohort, with a mean age of 57 (IQR 43 and 66, respectively). Of these, six underwent a secondary urological procedure at the time of ureterolysis (1 ureteroureterostomy, 2 ureteoneocystostomy, and 3 ureteroneocystostomy with psoas hitch/bladder flap). The overall complication rate was 12%. Of the patients affected, 92% experienced only Clavien grade I or II complications (wound or urinary infection). Only one patient required return to the operating room (Clavien III) and there were no high-grade complications (Grade IV or V).
Ureterolysis for retroperitoneal fibrosis is an uncommonly performed surgery with generally low incidence of post-operative complications. Ureterolysis may represent a safe treatment option for ureteric obstruction secondary to retroperitoneal fibrosis.
输尿管松解术是一种用于治疗腹膜后纤维化的不常施行的手术。本研究旨在利用一个大型多中心数据库评估接受输尿管松解术治疗腹膜后纤维化患者的短期术后结局。
使用美国外科医师学会国家质量改进计划数据库,对2006年1月1日至2016年12月31日期间接受输尿管松解术治疗腹膜后纤维化的患者进行回顾性研究。纳入由泌尿外科医生将输尿管松解术作为主要手术操作治疗腹膜后纤维化的患者。根据Clavien-Dindo分类系统记录并整理术后30天内的并发症情况。确定输尿管松解术时进行的二次重建泌尿外科手术(输尿管输尿管吻合术、输尿管膀胱吻合术以及带腰大肌悬吊/膀胱瓣的输尿管膀胱吻合术)的发生率。
该队列纳入了100例患者(51例男性,49例女性),平均年龄为57岁(四分位间距分别为43岁和66岁)。其中,6例患者在输尿管松解术时接受了二次泌尿外科手术(1例输尿管输尿管吻合术,2例输尿管膀胱吻合术,3例带腰大肌悬吊/膀胱瓣的输尿管膀胱吻合术)。总体并发症发生率为12%。在受影响的患者中,92%仅经历了Clavien I级或II级并发症(伤口或泌尿系统感染)。只有1例患者需要返回手术室(Clavien III级),且没有高级别并发症(IV级或V级)。
输尿管松解术治疗腹膜后纤维化是一种不常施行的手术,术后并发症发生率总体较低。输尿管松解术可能是治疗腹膜后纤维化继发输尿管梗阻的一种安全治疗选择。